Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Optifer is an oral heme-bound iron (heme-iron) preparation, specifically a heme iron polypeptide, used for the treatment and prevention of iron deficiency anemia (IDA), including pregnancy-associated IDA. Unlike traditional inorganic iron salts such as ferrous sulfate, which are absorbed via the divalent metal transporter 1 (DMT1) and often cause gastrointestinal irritation, Optifer is absorbed through the Heme Carrier Protein-1 (HCP-1) in the intestinal epithelium. This mechanism typically results in superior bioavailability and a lower incidence of side effects like nausea and constipation. Clinical studies, including those conducted in Kuwait and Kazakhstan, have demonstrated its efficacy in significantly improving hemoglobin and ferritin levels, often showing comparable results to intravenous iron treatments with better patient compliance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heme iron polypeptide (Ahmadi Hospital).